Recombinant Vaccinia-Tricom Vaccine
Intestinal Adenocarcinoma of the Stomach
National Cancer Institute (NCI)vaccinePhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 31/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Intestinal Adenocarcinoma of the Stomach cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eloxatin University of Chicago | Phase 1 | CC |
FLUOROURACILUM University of Chicago | Phase 1 | CC |
Sargramostim National Cancer Institute (NCI) | Phase 1 | CC |
Irinotecan University of Chicago | Phase 1 | CC |
Recombinant Fowlpox-Gm-Csf National Cancer Institute (NCI) | Phase 1 | CC |
Recombinant Fowlpox-CEA(6D) National Cancer Institute (NCI) | Phase 1 | CC |
Same molecule, other indications
Recombinant Vaccinia-Tricom Vaccine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →